New patient trials surrounding this compound, specifically the 120mg formulation referred to as ZPHC, indicate a considerable effect on weight decrease and related metabolic factors. Researchers anticipate that this innovative acting , targeting both GLP-1 and GIP receptors , has the potential to provide a major breakthrough in the approach of obe